dc.contributor.author | Kıyak, Hüseyin | |
dc.contributor.author | Karacan, Tolga | |
dc.contributor.author | Bulut, Berk | |
dc.contributor.author | Özyürek, Eser | |
dc.contributor.author | Gedikbaşı, Ali | |
dc.contributor.author | Api, Murat | |
dc.date.accessioned | 2020-01-02T12:01:51Z | |
dc.date.available | 2020-01-02T12:01:51Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Hüseyin, K., Tolga, K., Berk, B., Eser, O., Ali, G. ve Murat, A (2019). Recurrent endometrioma in infertile patients has worse outcome than primary endometrioma in response to controlled ovarian hyperstimulation and intrauterine insemination. Journal of Reproductive Medicine, 64(7-8), 282-290. | en_US |
dc.identifier.issn | 0024-7758 | |
dc.identifier.issn | 1943-3565 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/4865 | |
dc.description.abstract | Objective: To investigate the difference in the effectiveness of controlled ovarian hyperstimulation and intrauterine insemination (COH + IUI) on pregnancy rates in patients with primary and recurrent endometriomas.
Study Design: Multicenter, retrospective cohort study done in 3 tertiary referral centers. Included in the study were (1) primary infertility patients with endometriomas who had no other probable cause for infertility, (2) those who underwent 2 cycles of COH + IUI, provid- ed the sperm test was nor- mal, (3) those who had at least 1 patent fallopian tube, and (4) those whose ovarian reserve was normal with ovulatory cycles. Therapy for COH was hMG (menotropin) or recombinant follicle-stimulating hormone (follitropin alfa, beta) at 75 IU/d starting from day 3. Trigger was done by 5,000-10,000 human chorionic gonadotropin or choriogonadotropin alfa 250 mu g/0.5 mL when the dominant follicle size reached 18 mm.
Results: The ongoing pregnancy rates in patients with primary endometrioma were 14.4% per patient and 8.06% per cycle. In patients with recurrent endometrioma, the ongoing pregnancy rates were 6.06% per patient and 3.4% per cycle. Ongoing pregnancy rates were significantly higher in patients with primary endometrioma than in recurrent endometrioma patients.
CONCLUSION: COH + IUI may be recommended even before surgery for couples with primary endometriomas when there is no other infertility factor. COH + IUI treatment is not recommended for recurrent endometrioma patients. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Science Printers and Publishers Inc. | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Adenomyosis | en_US |
dc.subject | Artificial Insemination | en_US |
dc.subject | Assisted Reproductive Techniques | en_US |
dc.subject | Deep Infiltrative Endometriosis | en_US |
dc.subject | Endometrioma | en_US |
dc.subject | Endometriosis | en_US |
dc.subject | Infertility | en_US |
dc.subject | Intrauterine Insemination | en_US |
dc.subject | Ovulation Induction | en_US |
dc.subject | Pelvic Pain/Diagnosis | en_US |
dc.title | Recurrent endometrioma in infertile patients has worse outcome than primary endometrioma in response to controlled ovarian hyperstimulation and intrauterine insemination | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Reproductive Medicine | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9442-2690 | en_US |
dc.identifier.volume | 64 | en_US |
dc.identifier.issue | 7-8 | en_US |
dc.identifier.startpage | 282 | en_US |
dc.identifier.endpage | 290 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q3 | en_US |